The data were analysed using the Michaelis-Menten model with a nonlinear regression curve fit in Graph Pad Prism (version 5.01) software. The concentrations of peptide were 0, 5, 10, 20, and 40 μM. (B) ELISA binding of Ltc 1 to dengue NS2B-NS3pro. Increasing concentrations of purified dengue NS2B-NS3pro

(0, 20, 30 and 50 nM/well) were bound to black 96-well plate with transparent bottom. The Ltc 1 peptide labeled with FITC fluorescence dye (0, 0.1, 0.5, 1, 5, 10, 20, 30, 50 nM) were prepared in were bound to plates for 3 h on ice in dark place. the fluorescence signals of bound Ltc 1 were detected after washing steps using fluorescence spectrophotometer. (C) Determination of the IC50 value of the Ltc 1 peptide at normal physiologic human temperature (37°C). (D) Determination of the IC50 value of Ltc 1 peptide at the temperature of a human with a high fever (40°C). The effect of the Ltc 1 peptide on cell proliferation and assessment of antiviral activity Selleck LEE011 The cytotoxic effect of Ltc 1 peptide on cell viability

was measured using a non-radioactive cell proliferation assay. The CC50 value of the Ltc 1 peptide obtained via the optimisation steps was estimated to be approximately 52.51 ± 3.6 μM as shown in Figure  3A. The Ltc 1 peptide induces cellular changes that lead to cell apoptosis [21]. This activity may decrease the formation of plaques leading to a false interpretation of antiviral activity. To clarify this issue, we examined the mTOR inhibitor effects of increasing concentrations of peptide on real time cell proliferation using the Real-Time Cellular Analysis (RTCA) system. The results showed that the effects of the peptide on cell proliferation were insignificant at 25 μM for 110 h because the cell index was similar to the untreated control cells. Cell proliferation was significantly decreased at 50 μM after 66 h of incubation of the HepG2 cells with the peptide (Figure  3B).Concentrations higher than 50 μM

for peptide were toxic to the cells at all time-points of the RTCA assay. Therefore, a concentration of 25 μM was identified as the maximal non-toxic dose (MNTD) of the Ltc 1 peptide used in the following experiment to evaluate the antiviral activity of the Ltc 1 peptide. The antiviral activity of the Ltc 1 peptide was initially evaluated by immunostaining and this website western blot targeting the DENV2 NS1 protein. The results showed a significant reduction of viral particles after treatment with the Ltc 1 peptide (Figure  3C). This result was further confirmed by western blot analysis that showed significant reduction in the expression of the viral NS1 protein after treatment of the infected cells with peptide. This result was normalised to beta-actin as an endogenous gene to eliminate loading errors (Figure  3D). Figure 3 Effect of the Ltc 1 peptide on cells proliferation and viral replication in HepG2 cells. (A) The cytotoxic effect of the Ltc 1 peptide on cell viability was measured by non-radioactive cell proliferation assay.